LataMed AI Corp. (OTC: LMED), a healthcare technology company developing digital health and artificial intelligence solutions for Latin America, announced its participation in the Artificial Intelligence & Health Markets 2026 conference, scheduled for August 13-14, 2026, at Universidad Santa Maria in Caracas, Venezuela. The event, organized through its Venezuelan operating subsidiary LATAMEDAI VE, will bring together students, faculty, and professionals from systems engineering and healthcare disciplines, including pharmacy, dentistry, and laboratory sciences.
The company will be represented by Dr. Kevin Rodan Levy, Chief Executive Officer, and Carlos Pena, Chief Financial Officer. Their presentation will address the evolving role of artificial intelligence in healthcare, systems engineering, digital infrastructure, and professional decision-making. LataMed AI intends to discuss how AI-supported tools can assist healthcare professionals with medical-data evaluation, clinical workflows, and operational decision-making, as well as how automation may enhance the organization, reliability, and efficiency of technology systems in healthcare and other complex environments.
A key emphasis of the presentation will be the importance of maintaining qualified professional oversight when implementing AI. The company stresses that its technologies are designed to augment human capabilities and support informed decision-making, not replace the independent judgment of healthcare professionals, engineers, laboratory personnel, or other qualified individuals. This stance is critical as AI becomes more integrated into healthcare, where ethical considerations and patient safety are paramount.
Additional conference topics will include the integration of AI and automation into existing systems, responsible data use, privacy and information security, operational risk management, and practical considerations in developing and deploying technology in healthcare settings. These discussions are vital as Latin America increasingly adopts digital health solutions, and the region's future professionals must be prepared to navigate the complexities of AI implementation.
LataMed AI also plans to discuss the continued development of its healthcare technology ecosystem, including CardioAI, PulmoAI, and NeuroAI. These AI-supported platforms are being developed to assist healthcare professionals in evaluating and managing cardiovascular, pulmonary, and neurological health information. However, they remain subject to continued development, testing, regulatory requirements, and commercial implementation, highlighting the need for rigorous validation before widespread use.
Dr. Kevin Rodan Levy commented, "Artificial Intelligence & Health Markets 2026 provides an important opportunity to engage directly with students, educators, and future professionals who will help shape the responsible use of artificial intelligence in healthcare and systems engineering. Our objective is to share practical perspectives on how intelligent technologies can support professional decision-making, improve digital workflows, and contribute to the continued development of healthcare infrastructure in Latin America."
Management believes that engagement with universities can increase awareness of emerging healthcare technologies, encourage responsible discussion, and strengthen relationships with future professionals. This participation also allows the company to gain insights from students, educators, and researchers as it develops solutions for the Latin American market. The event is part of LataMed AI's broader strategy to support education and the responsible adoption of digital healthcare infrastructure in the region.
The conference does not constitute an endorsement of LataMed AI or its technologies by Universidad Santa Maria, and does not guarantee future collaborations or financial benefits. Nonetheless, the company's involvement underscores its commitment to fostering dialogue on AI's role in healthcare, a topic of growing importance as technology transforms the industry. For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
